Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Plasmablastic Lymphoma × Dexamethasone × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 171 Lymphoma 93 Leukemia 63 Burkitt Lymphoma 56 Lymphoma, Non-Hodgkin 49 Lymphoma, Large B-Cell, Diffuse 43 Lymphoma, Mantle-Cell 38 Lymphoma, Follicular 30 Recurrence 29 Hodgkin Disease 29 Waldenstrom Macroglobulinemia 27 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27 Leukemia, Lymphocytic, Chronic, B-Cell 26 Multiple Myeloma 21 Lymphoma, B-Cell, Marginal Zone 17 Lymphoma, Extranodal NK-T-Cell 16 Leukemia, Biphenotypic, Acute 16 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 13 Leukemia, Myeloid, Acute 13 Lymphoma, B-Cell 12 Lymphoma, Large-Cell, Immunoblastic 11 Lymphoma, T-Cell, Peripheral 10 Neoplasms 9 Lymphoma, Large-Cell, Anaplastic 9 Lymphoma, T-Cell, Cutaneous 8 Lymphoma, T-Cell 7 Intraocular Lymphoma 6 Hematologic Neoplasms 6 Blast Crisis 6 Sezary Syndrome 5

Interventions

Etoposide 6 Vincristine 5 Prednisone 5 Doxorubicin 5 Cyclophosphamide 5 Rituximab 4 prednylidene 3 deltacortene 3 daratumumab 2 Cytarabine 2 varlilumab 1 pomalidomide 1 merphos 1 ixazomib 1 carmustine, poliferprosan 20 drug combination 1 belantamab mafodotin 1 Vorinostat 1 Specimen Handling 1 Peripheral Blood Stem Cell Transplantation 1 Nivolumab 1 Methotrexate 1 Melphalan 1 Magnetic Resonance Spectroscopy 1 Immunoglobulin G 1 Hydrocortisone 1 Disulfides 1 Dexamethasone 1 Carmustine 1 CT-P10 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04915248 2025-12-24

FIL_DALYA

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting

Plasmablastic Lymphoma, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡